Abstract
Stability-indicating reversed-phase high-performance liquid chromatography method was developed and validated for the simultaneous estimation of ezetimibe and glimepiride. Chromatographic separation was achieved with a Shimadzu’s high performance liquid chromatograph and PhenomenexL1 analytical C18 column with a mobile phase of acetonitrile:ammonium acetate buffer (30 mM):methanol (50:45:5 %, v/v/v). The flow rate was set at 1.5 ml/min and the detection wavelength was 232 nm. Quality by design approach was employed for optimization of method parameters like proportion of mobile phase, concentration of buffer and a model highlighting the design space was generated. This developed chromatographic method gave well resolved symmetric peaks. Ezetimibe and glimepiride were eluted at 6.7 and 4.4 min, respectively. This method was validated according to ICH Q2(R1) guideline. The method was linear in range of 50-400 µg/ml for ezetimibe and 5-40 µg/ml for glimepiride with r2=0.9999 and 0.9996, respectively. The sample recoveries were in good agreement with the respective label claim, which suggested non-interference from formulation additives in the estimation. Forced degradation studies were carried out and the stressed samples were analysed using the developed method.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.